Fulcrum Therapeutics (FULC) on Saturday reported positive initial results from the ongoing 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease.
“We are highly encouraged by these initial data from the 20 mg cohort, which